PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (VTRS) (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the ...
The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...
"We are pleased with the profile our investigational XULANE LO low dose patch demonstrated in this Phase 3 study," said Viatris Chief R&D Officer Philippe Martin. "The data underscores our confidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback